We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina Inc. (ILMN - Free Report) is a medical company that focuses on DNA sequencing and array-based technologies; they serve their customers in the research, clinical, and applied markets. Illumina’s products are used throughout life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Shares Rally on Q2 Results
Just a few days ago, Illumina, which sits at a #1 (Strong Buy) on the Zacks Rank, posted great second quarter numbers across the board. Shares rallied over 7% as a result, suggesting the market was impressed by the medical stock’s performance.
Both its top and bottom line easily beat the Zacks Consensus Estimate, with revenues surging 25% year-over-year.
Cash flow from operations hit $295 million, while free cash flow was $218 million for the quarter.
Research and development (R&D) expenses for Q2 were $151 million compared to $130 million in the prior year period. As a percentage of revenues, non-GAAP R&D expenses were 18.2%.
Additionally, sequencing consumables, array consumables, and lab and other services each grew over 30% in comparison to Q2 2017.
ILMN now expects revenue growth of roughly 20% for the fiscal year and non-GAAP EPS between $5.35 to $5.45.
Strong Earnings Outlook
For ILMN, its bottom line is trending upward for the foreseeable future.
Earnings are expected to grow about 7% for the current quarter, and three analysts have revised their estimates higher over the past two months compared to none lower.
Current fiscal year figures are looking pretty good, with two upwards estimates in the last 60 days. The Zacks Consensus estimate trend has jumped five cents from $4.86 per share to $4.91 per share.
Next year is looking solid as well, with earnings expected to grow over 17%; the consensus has increased 17 cents in the past two months.
What’s Next for ILMN?
Shares of Illumina have gained more than 85% in the past one-year period and have increased about 48% year-to-date. In comparison, the S&P 500 has gained 14% in the same time period and 5.3%, respectively.
Its industry, Medical—Biomedical and Genetics, has lost about 1.1% year-to-date, but the group sits in the top 40% of all industries ranked by the Zacks Industry Rank. ILMN, though, is one of the top performers, especially when compared to industry peers like Sangamo Therapeutics (SGMO - Free Report) and Biohaven Pharmaceutical (BHVN - Free Report) .
Taking into account its impressive industry standing, as well as its expected earnings growth, Illumina could be an exciting opportunity for investors looking to get in to the broader medical space right now.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bull of the Day: Illumina (ILMN)
Illumina Inc. (ILMN - Free Report) is a medical company that focuses on DNA sequencing and array-based technologies; they serve their customers in the research, clinical, and applied markets. Illumina’s products are used throughout life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Shares Rally on Q2 Results
Just a few days ago, Illumina, which sits at a #1 (Strong Buy) on the Zacks Rank, posted great second quarter numbers across the board. Shares rallied over 7% as a result, suggesting the market was impressed by the medical stock’s performance.
Both its top and bottom line easily beat the Zacks Consensus Estimate, with revenues surging 25% year-over-year.
Cash flow from operations hit $295 million, while free cash flow was $218 million for the quarter.
Research and development (R&D) expenses for Q2 were $151 million compared to $130 million in the prior year period. As a percentage of revenues, non-GAAP R&D expenses were 18.2%.
Additionally, sequencing consumables, array consumables, and lab and other services each grew over 30% in comparison to Q2 2017.
ILMN now expects revenue growth of roughly 20% for the fiscal year and non-GAAP EPS between $5.35 to $5.45.
Strong Earnings Outlook
For ILMN, its bottom line is trending upward for the foreseeable future.
Earnings are expected to grow about 7% for the current quarter, and three analysts have revised their estimates higher over the past two months compared to none lower.
Current fiscal year figures are looking pretty good, with two upwards estimates in the last 60 days. The Zacks Consensus estimate trend has jumped five cents from $4.86 per share to $4.91 per share.
Next year is looking solid as well, with earnings expected to grow over 17%; the consensus has increased 17 cents in the past two months.
What’s Next for ILMN?
Shares of Illumina have gained more than 85% in the past one-year period and have increased about 48% year-to-date. In comparison, the S&P 500 has gained 14% in the same time period and 5.3%, respectively.
Illumina, Inc. Price and Consensus
Illumina, Inc. Price and Consensus | Illumina, Inc. Quote
Its industry, Medical—Biomedical and Genetics, has lost about 1.1% year-to-date, but the group sits in the top 40% of all industries ranked by the Zacks Industry Rank. ILMN, though, is one of the top performers, especially when compared to industry peers like Sangamo Therapeutics (SGMO - Free Report) and Biohaven Pharmaceutical (BHVN - Free Report) .
Taking into account its impressive industry standing, as well as its expected earnings growth, Illumina could be an exciting opportunity for investors looking to get in to the broader medical space right now.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>